The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-14. Anything still debated is marked as such rather than presented as settled.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
The basic idea of a ranking of the world's organisms goes back to Aristotle's biology. In his History of Animals, where he ranked animals over plants based on their ability to move and sense, and graded the animals by their reproductive mode, live birth being "higher" than laying cold eggs, and possession of blood, warm-blooded mammals and birds again being "higher" than "bloodless" invertebrates. Aristotle's non-religious concept of higher and lower organisms was taken up by natural philosophers during the Scholastic period to form the basis of the Scala Naturae. The scala allowed for an ordering of beings, thus forming a basis for classification where each kind of mineral, plant and animal could be slotted into place. In medieval times, the great chain was seen as a God-given and unchangeable ordering. In the Northern Renaissance, the scientific focus shifted to biology; the threefold division of the chain below humans formed the basis for Carl Linnaeus's Systema Naturæ from 1737, where he divided the physical components of the world into the three familiar kingdoms of minerals, plants and animals.
In December 2024, Trump stated a further proposal for the United States to purchase Greenland from Denmark, describing "ownership" and control of the island as "an absolute necessity" for national security purposes. This builds upon a prior offer from Trump to buy Greenland during his first term, which the Danish Realm refused, causing him to cancel his August 2019 visit to Denmark. On January 7, 2025, Trump's son Donald Trump Jr. visited Greenland's capital city Nuuk alongside Charlie Kirk to hand out MAGA hats. At a press conference the following day, Trump refused to rule out military or economic force to take over Greenland or the Panama Canal. However, he did rule out military force in taking over Canada. On January 14, the Trump-affiliated Nelk Boys also visited Nuuk, handing out dollar bills to locals. On January 16, the CEOs of major Danish companies Novo Nordisk, Vestas and Carlsberg among others were assembled for a crisis meeting in the Ministry of State to discuss the situation. On the subsequent day, former chief executive Friis Arne Petersen in the Danish Ministry of Foreign Affairs described the situation as "historically unheard of", while Noa Redington, special adviser to former prime minister Helle Thorning-Schmidt, compared the international pressure on Denmark that during the 2005 Jyllands-Posten Muhammad cartoons controversy. On February 12, 2025, a bill was introduced in Congress to advance efforts to acquire Greenland and rename it Red, White, and Blueland.
Collective cell migration is studied over many model species. Border cells in flies (Drosophila melanogaster): the border cells migrate during the differentiation of egg cells to be ready for fertilization. The lateral line in zebrafish: collective cell migration from head to tails is essential to the development of the sensory system of the fish. The sensors of the lateral line measure the flow over the body-surface of the fish. Wound healing: collective cell migration is an essential part in this healing process, wound area is closed by the migrating cells. Wound healing is commonly studied in vitro using cell lines such as Madin-Darby Canine Kidney cells. Neural crest cells in mice, Leghorn chicks, amphibians (Xenopus laevis), and fish (zebrafish): collective migration of neural crest cells occurs during embryo development of vertebrates. They migrate long distances from the head (neural tube) to give rise to different tissues. Spreading of cancer (metastasis): common complication of cancer involve formation of new tumors (secondary tumors), as a result of migration of cancer cells from the primary tumor. Similar to collective cell migration in development and wound healing, cancer cells also undergo epithelial to mesenchymal transition (EMT), that reduces cell-cell adhesions and allows cancer spreading. The diagram on the right shows:
== Sources == B vitamins are found in abundance in meat, eggs, and dairy products. Processed carbohydrates such as sugar and white flour tend to have lower B vitamin content than their unprocessed counterparts. For this reason, it is common in many countries (including the United States) that the B vitamins thiamine, riboflavin, niacin, and folic acid are added back to white flour after processing. This is referred to as "enriched flour" on food labels. B vitamins are particularly concentrated in meat such as turkey, tuna and liver. Sources for B vitamins also include spinach, legumes (pulses or beans), whole grains, asparagus, potatoes, bananas, chili peppers, breakfast cereals. The B12 vitamin is not abundantly available from plant products (although it has been found in moderate abundance in fermented vegetable products, certain seaweeds, and in certain mushrooms, with the bioavailability of the vitamin in these cases remaining uncertain), making B12 deficiency a legitimate concern for those maintaining a vegan diet. Manufacturers of plant-based foods will sometimes report B12 content, leading to confusion about what sources yield B12. The confusion arises because the standard US Pharmacopeia (USP) method for measuring the B12 content does not measure the B12 directly. Instead, it measures a bacterial response to the food. Chemical variants of the B12 vitamin found in plant sources are active for bacteria, but cannot be used by the human body. This same phenomenon can cause significant over-reporting of B12 content in other types of foods as well.
Sources: en.wikipedia.org
=== Near-surface divergence === In the United States, as a high-pressure system moves eastward out to the Atlantic, northerly winds are reduced along the southeast coast. If northeasterly winds persist in the southern damming region, net divergence is implied. Near-surface divergence reduces the depth of the cold dome as well as aid the sinking of air, which can reduce cloud cover. The reduction of cloud cover permits solar heating to effectively warm the cold dome from the surface up.
Cabinets of Lower Saxony Since 1948, politics in the state have been dominated by the centre-right Christian Democratic Union (CDU) and the centre-left Social Democratic Party (SPD). Lower Saxony was one of the origins of the German environmentalist movement in reaction to the state government's support for underground nuclear waste disposal. This led to the formation of the German Green Party in 1980. Germany's multi-party system generally requires coalitions to be made because parties usually do not have outright majorities. The Minister-President heads the state government, acting as a head of state (even if the federated states have the status of a state do not establish the office of a head of state but merge the functions with the head of the executive branch) as well as the government leader. They are elected by the Landtag of Lower Saxony. The former Minister-President, Christian Wulff, led a coalition of his CDU with the Free Democratic Party between 2003 and 2010. In the 2008 election, the ruling CDU held on to its position as the leading party in the state, despite losing votes and seats. The CDU's coalition with the Free Democratic Party retained its majority although it was cut from 29 to 10. The election also saw the entry into the state parliament for the first time of the leftist The Left party. On 1 July 2010 David McAllister was elected Minister-President. After the state election on 20 January 2013, Stephan Weil of the Social Democrats was elected as the new Minister-President. He governed in coalition with the Greens.
ATC code A10 Drugs used in diabetes is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. Subgroup A10 is part of the anatomical group A Alimentary tract and metabolism. Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QA10. National versions of the ATC classification may include additional codes not present in this list, which follows the WHO version. A10AB01 Insulin (human) A10AB02 Insulin (beef) A10AB03 Insulin (pork) A10AB04 Insulin lispro A10AB05 Insulin aspart A10AB06 Insulin glulisine A10AB30 Combinations === A10AC Insulins and analogues for injection, intermediate-acting === A10AC01 Insulin (human) A10AC02 Insulin (beef) A10AC03 Insulin (pork) A10AC04 Insulin lispro A10AC30 Combinations
Sources: en.wikipedia.org
Polish refugees were housed at dedicated settlements set up at Marandellas and Rusape, two towns about 40 km (25 mi) apart to the south-east of Salisbury, from 1943. There were similar camps in Kenya, Nyasaland, Tanganyika, Northern Rhodesia and South Africa. The Polish settlements in Southern Rhodesia were run jointly by local authorities and the Polish consulate in Salisbury; the Polish government-in-exile in London provided funding. Transport back to Europe picked up sharply as the war came to a close, and by October 1945 less than 2,000 Polish refugees remained. Colonial officials were reluctant to let the Poles stay indefinitely, asserting that they were not culturally British enough and might have communist connections or sympathies, but most of those who remained showed little inclination to leave. Southern Rhodesia ultimately allowed around 726 Polish refugees to settle permanently after the war.
==== Cancer health claims ==== The U.S. Food and Drug Administration initiated a process of reviewing and approving food and dietary supplement health claims in 1993. Reviews of petitions results in proposed claims being rejected or approved. If approved, specific wording is allowed on package labels. In 1999, a second process for claims review was created. If there is not a scientific consensus on the totality of the evidence, a Qualified Health Claim (QHC) may be established. The FDA does not "approve" qualified health claim petitions. Instead, it issues a Letter of Enforcement Discretion that includes very specific claim language and the restrictions on using that wording. The first QHCs relevant to vitamin E were issued in 2003: "Some scientific evidence suggests that consumption of antioxidant vitamins may reduce the risk of certain forms of cancer." In 2009, the claims became more specific, allowing that vitamin E might reduce the risk of renal, bladder and colorectal cancers, but with required mention that the evidence was deemed weak and the claimed benefits highly unlikely. A petition to add brain, cervical, gastric and lung cancers was rejected. A further revision, May 2012, allowed that vitamin E may reduce risk of renal, bladder and colorectal cancers, with a more concise qualifier sentence added: "FDA has concluded that there is very little scientific evidence for this claim." Any company product label making the cancer claims has to include a qualifier sentence.
Let God Sort Em Out is the fourth studio album by the American hip-hop duo Clipse. Self-released on July 11, 2025, it marks the duo's first album since Til the Casket Drops (2009); Pusha T and Malice split in 2010, before reuniting in 2019 and starting work on the album in 2023. Longtime collaborator and mentor Pharrell Williams returns as the album's executive and only producer after splitting with his Neptunes collaborator Chad Hugo; he also appears as a guest, alongside Ab-Liva (of Clipse side-project Re-Up Gang), John Legend, Kendrick Lamar, Nas, Stove God Cooks, The-Dream, Tyler, the Creator, and the choir ensemble Voices of Fire. Additional contributors include Lenny Kravitz and Stevie Wonder. Rumors of a new Clipse album started in 2023 when Williams, who became creative director of menswear at luxury fashion house Louis Vuitton the same year, included a new Clipse song in the soundtrack to the Louis Vuitton Men's Spring-Summer 2024 Show. The album's recording sessions were primarily split between studios in the trio's home state of Virginia and the Louis Vuitton headquarters in Paris, France. Originally planned for a 2024 release, the album was delayed when the duo's then-label Def Jam Recordings and its parent company Universal Music Group demanded Lamar's guest verse on "Chains & Whips" be either censored or removed.
=== Part Three === A third part was filmed by the Purchase Brothers. A fundraising campaign was held via Indiegogo in order to fund the film's special effects, but failed to meet its goal. On August 23, 2013, a teaser for Escape from City 17: Part Three was released.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.